Skip to content

Released Mar 28, 2024, after the close

10-K filed Mar 28, 2024, 88 days after period end · 0001390478-24-000004

Q4 2023 · 10-K

derived · Computed from the longer spans the company filed.

Revenue$0.00derived— vs Q4 2022no prior Q3 2023 on file
Net Income-$8.14MderivedN/M vs Q4 2022N/M vs Q3 2023
EPS, diluted—Not derived. Share counts vary by quarter.
Operating Incomederived-$8,177,000N/M
Operating Cash Flowderived-$4,825,000N/M

What the release said

The release

Same quarter

MetricQ4 2023derived from reported figuresQ4 2022derived from reported figuresQ4 2021derived from reported figuresQ4 2020derived from reported figures
Revenue$0.00$0.00$0.00$1.90M
Net Income-$8.14M-$9.12M-$6.60M-$3.72M

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

SELLAS Life Sciences Group, Inc. · CIK 1390478 · Engraved from SEC EDGAR